NR3C2 and pulmonary arterial hypertension: It is reported that increased renin–angiotensin activity and elevated levels of aldosterone were noted in patients with pulmonary artery hypertension (PAH), which indicates an important role for angiotensin and mineralocorticoid receptor antagonists in the treatment of PAH [22].